CHMP recommends market authorisation for liposomal amikacin (Arikayce liposomal)

This inhalation suspension is intended to be licensed for the treatment of non-tuberculous mycobacterial lung infections caused by Mycobacterium avium Complex in adults with limited treatment options who do not have cystic fibrosis.

European Medicines Agency